Literature DB >> 8181283

Prospective study on the occurrence of withdrawal in critically ill children who receive fentanyl by continuous infusion.

R Katz1, H W Kelly, A Hsi.   

Abstract

OBJECTIVE: To determine the occurrence of narcotic withdrawal in critically ill children who receive continuous infusions of fentanyl.
DESIGN: Prospective case series.
SETTING: A university hospital pediatric intensive care unit. PATIENTS: Twenty-three children, aged 1 wk to 22 months (mean 6 months), who required assisted mechanical ventilation and who received continuous infusions of fentanyl for > 24 hrs.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Total fentanyl dose received, length of infusion, and peak infusion rate were recorded. Patients were evaluated for narcotic withdrawal by the Neonatal Abstinence Scoring System of Finnegan. Children with scores of > or = 8 were considered to have narcotic withdrawal. Withdrawal was observed in 13 (57%) of 23 infants. Total fentanyl dose (2.96 +/- 4.10 vs. 0.53 +/- 0.37 mg/kg, p < .005) and length of fentanyl infusion (13.1 +/- 11.3 vs. 3.8 +/- 1.5 days, p < .0001) were significantly greater in those infants with narcotic withdrawal than in those infants with no withdrawal, respectively. Peak fentanyl infusion rate (9.9 +/- 7.8 vs. 9.2 +/- 4.4 micrograms/kg/hr) did not differ significantly between the two groups. A total fentanyl dose of > 2.5 mg/kg or a duration of infusion of > 9 days was 100% predictive of withdrawal.
CONCLUSIONS: Continuous infusions of fentanyl produce a high occurrence rate of narcotic withdrawal when administered to critically ill children. This effect is both dose- and duration-dependent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8181283     DOI: 10.1097/00003246-199405000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  38 in total

Review 1.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Can we use methadone for analgesia in neonates?

Authors:  S K Chana; K J Anand
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-09       Impact factor: 5.747

3.  Dexmedetomidine: Are There Going to be Issues with Prolonged Administration?

Authors:  Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

Review 4.  Pharmacological therapy for analgesia and sedation in the newborn.

Authors:  K J S Anand; R W Hall
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11       Impact factor: 5.747

Review 5.  Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: a systematic review and conceptual model.

Authors:  Kaitlin M Best; Joseph I Boullata; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2015-02       Impact factor: 3.624

6.  Dosing evaluation of continuous intravenous fentanyl infusions in overweight children: a pilot study.

Authors:  Emily C Gish; Donald Harrison; Andrew K Gormley; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

7.  Use of methadone for prevention of opioid withdrawal in critically ill children.

Authors:  Sonia A Jeffries; Rumi McGloin; Alexander F Pitfield; Roxane R Carr
Journal:  Can J Hosp Pharm       Date:  2012-01

8.  Use of methadone for opioid weaning in children: prescribing practices and trends.

Authors:  Kazim Giby; Régis Vaillancourt; Nisha Varughese; Christina Vadeboncoeur; Annie Pouliot
Journal:  Can J Hosp Pharm       Date:  2014-03

9.  Morphine-enhanced apoptosis in selective brain regions of neonatal rats.

Authors:  Dusica Bajic; Kathryn G Commons; Sulpicio G Soriano
Journal:  Int J Dev Neurosci       Date:  2013-03-07       Impact factor: 2.457

10.  Long-term behavioral effects in a rat model of prolonged postnatal morphine exposure.

Authors:  Michael M Craig; Dusica Bajic
Journal:  Behav Neurosci       Date:  2015-07-27       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.